Photo of Taru Muranen,  PhD

Taru Muranen, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 943-9055


tmuranen@bidmc.harvard.edu

Taru Muranen, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Principal Investigator, Muranen Lab, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My laboratory studies how tumor microenvironment influences drug responses in pancreatic and breast cancer. Our laboratory uses co-culture models, tumor organoids, 3D model systems and proteomics to study how cancer cells develop drug resistance and how tumor microenvironment and the extracellular matrix microenvironment influence tumor cells responses to therapies. Our goal is to develop novel more effective therapies to abrogate tumor microenvironment mediated drug resistance.

Publications

Powered by Harvard Catalyst
  • Muranen T, Iwanicki MP, Curry NL, Hwang J, DuBois CD, Coloff JL, Hitchcock DS, Clish CB, Brugge JS, Kalaany NY. Starved epithelial cells uptake extracellular matrix for survival. Nat Commun 2017; 8:13989. PubMed
  • Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS. ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Res 2016; 76:7168-7180. PubMed
  • Muranen T, Brugge JS. Moving Closer To Victory. Cold Spring Harb Symp Quant Biol 2017; 81:281-288. PubMed
  • Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21:227-39. PubMed